We established our bio-repository in October 2002. One of the unique aspects of our biorepository is that it is based on post-clinical test samples. Although the post-clinical test sample-based storage is beneficial because ample clinical information is available for each sample and samples are to be refreshed regularly, many bio-bankers are hesitant to store them because of the possible problems of de-identification procedures and sample quality. Currently, we have two different types of sample, not de-identified status and de-identified status. Most of the samples for storage are not de-identified status. A portion of the samples are transferred to new tubes before and after being frozen, without clinical patient identifications and the status is de-identified. This tube transfer is the only de-identification procedure in our bio-repository so far. After a procedure of de-identification, these samples are stored. The de-identified samples are collected under various project-based schemes. The quality standards of our samples are established by two factors: pre-analytical quality control efforts, and record keeping of sample history by sample tracking system. All the samples have been phlebotomized under strict control of pre-analytical requirements. By record keeping of sample history with the sample tracking system, we can tell the exact temperature and elapsed time in various situations since the phlebotomy procedure or on arrival at the clinical laboratory. In this article, we will disclose how we have dealt with the de-identification procedure and sample quality.
INTRODUCTION
We established our bio-repository in October 2002. Since then, we have maintained it and reported our experiences on several occasions (1 -3) . Since 2002, we have focused on increasing the number of samples in our repository, and currently, we have more than 250 000 samples in our storage space (4 -7) . During that time, the attitude regarding bio-repositories has significantly changed from an emphasis on quantity to one on quality. The current major concerns of bio-bankers are how to acquire and maintain high-quality samples.
One of the unique aspects of our bio-repository is that it is based on post-clinical test samples. One frequently asked question is how to ensure the de-identification of samples and another concerns sample quality. Although the postclinical test sample-based storage is beneficial because ample clinical information is available for each sample and samples are to be refreshed regularly, many bio-bankers are hesitant to store them because of the possible problems of de-identification procedures and sample quality.
Thus, it is worthwhile to disclose in this article how we have overcome these obstacles.
PATIENTS AND METHODS

DE-IDENTIFICATION PROCEDURE
Blood is drawn from the patients at room temperature (Fig. 1) . The drawn blood tube with the patient ID is submitted to the clinical laboratory for routine laboratory testing. The status of blood samples is not de-identified (NdeID). Various clinical tests are performed, and the results are reported to the physicians. The post-clinical test samples are placed in the temporary storage at 48C from around 1 to 10 days in a moratorium status to ensure that the clinical test report is out and accepted. Upon completion of the moratorium, most of the blood samples are discarded as medical wastes.
The blood samples from immunological testing and a part of the blood samples from various clinical test settings are transferred to the bio-repository for final storage at 2208C. In this transfer, samples from immunological tests are transferred as NdeID status. Traditionally, in our hospital, the routine immunological test samples are stored and kept frozen in a 2208C cold room as long as possible, unless there is no space. We assume that most of the tumor marker studies are in immunological test categories and our hospital is one of the leading cancer hospitals in Japan, thus the doctors are remarkably accustomed to focus on tumor markers. Additionally, these particular immunological test samples are handled by the most advanced automation lineage in our laboratories and are automatically transferred from drawing tubes to storage tubes with patient ID. Daily sample size is around 300 in number (Table 1) , and this category has various cancer patients, in other words, can provide a broad spectrum of cancer samples. Thus, when having established a bio-repository in our hospital, we decided to re-utilize this resource and continue to store and organize samples of immunological test categories.
We also store samples other than from immunological tests and these are from various clinical test settings. Samples from various clinical test settings are transferred to new tubes without clinical patient IDs and the status is de-identified (deID). After a procedure of de-identification, these samples are stored. Samples from various clinical test settings are collected under various project-based schemes. Current projects covered are those that belong to transfusionrelated cross-match test patients, pancreatic cancer patients, nutritional support team consultation-related patients and so on (Table 1) . Although most of the stored samples are discarded after 5 years, some samples of deID status can be utilized for other than re-testing of the particular patient.
If there is a request to use NdeID status samples previously collected and frozen, the sample transfer from tubes labeled with patient ID to new tubes with repository IDs is mandatory. The de-identification is to be performed at this point. The NdeID samples become deID samples. The samples were already frozen, thus it requires the thawing out of samples and so may affect the quality of samples. 
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De-identification procedure and sample quality
SAMPLE QUALITY
The quality standards of our samples are established by two factors: pre-analytical quality control efforts, and record keeping of sample history by sample tracking system. All the samples were phlebotomized under a strict control of pre-analytical requirements (8) . For instance, the following factors influenced clinical tests in some way: diet, starvation, exercise, stimulants and addictive drugs as biological influence factors, timing, sequence of diagnostic and therapeutic procedures, posture and tourniquet, site for blood draw, plasma or serum, tubes, transfer, processing, centrifuge and so on. In either outpatient or inpatient settings, a blood draw is under control to fit a particular clinical test. Usually, patients are required to take no meal, no vigorous exercise and no medications before a blood draw. After a blood draw, blood tubes are submitted to the clinical laboratory at room temperature as soon as possible, usually ,15 min for outpatients and ,60 min for inpatients. On arrival, serum samples are to be centrifuged at a suitable spin speed and then only the serum part is taken for further analysis. Plasma samples are to stand still for a while for separation of plasma and other cellular components. These efforts make it possible for sample quality to ensure that all the post-clinical test samples in our hospital meet the clinical test standard. The medical technologists in our laboratories perform various internal quality assurance procedures routinely and participate in an external quality assessment scheme regularly and must satisfy its requirements.
Record keeping of sample history by sample tracking system is another solution for providing a quality assurance procedure concerning sample quality in our hospital ( Table 2 ). The initial purpose of the sample tracking system is to shorten the turn-around-time of the clinical tests in general. This sample tracking system is set up for a design of prompt clinical test reply to the physicians. Recently, we noticed that by utilizing this tracking system, we can tell the exact temperature and elapsed time in various situations since the blood draw procedures or on arrival at the clinical laboratory.
RESULTS
DE-IDENTIFICATION PROCEDURE
The table indicates that we stored around 90 000 samples per year and around 350 samples per day (Table 1) . Currently, daily phlebotomized samples in our hospital are from about 500 to 700. Thus, from around 50% (350/700) to 70% (350/ 500) of samples are stored daily. Around 80% (76 468/ 90 000) of samples are NdeID and need a tube transfer procedure for de-identification. More than 250 000 samples mentioned in the Introduction section are all deID.
SAMPLE QUALITY
In the outpatient setting, sample history starts from the blood draw (Table 2) , because the new sample tracking system was introduced in this April. In the inpatient setting, sample history starts on arrival at the clinical laboratory. Unfortunately, we have no such sample tracking system in various inpatient wards because of the huge cost required to set up this type of sample tracking system. Approximately, 15 -60 min at room temperature is the inpatient sample history from blood draw to clinical laboratory arrival. Either from outpatient or from inpatient, almost 100% of samples, Jpn J Clin Oncol 2011;41(2) 297 exposed temperature and elapsed time are eventually recorded.
DISCUSSION
DE-IDENTIFICATION PROCEDURES
Since the introduction of the HIPPA Privacy Rule (9), various de-identification attempts were performed in the biobanking community (10) . These were mostly applied for document de-identification purposes. Our de-identification procedures are limited to physical samples. De-identification of physical samples is mainly accomplished by data scrubbing existing clinical IDs on a physical sample. Instead of actual data scrubbing, we transfer samples from a clinical ID tagged tube to a repository ID tagged tube. In other words, all the de-identification procedures in our bio-repository are simply based on tube transfer. The tube transfer procedure has a potential risk for a mis-transfer of samples. Currently, so far we have only a manual solution to avoid this risk. We try to handle a small number of tubes (for instance, 12 tubes) in each maneuver. We also check tube IDs and number repeatedly by different personnel.
To eliminate freezing and thawing, we have strongly encouraged doctors and researchers to discuss the samples needed before sample collection. Then, we retrieve the needed samples from our routine temporary storage refrigerator at 48C before being frozen.
Lastly, we believe the utilization of post-clinical test samples for this purpose is not so common. Thus, we explained how de-identification procedures are performed in our laboratory. Our experience will help other parties, especially clinical laboratory personnel, and they will take part in bio-banking of post-clinical test samples.
SAMPLE QUALITY
Many bio-bankers are now realizing that the quality of the samples is critical to research. Concerning sample quality, we propose from our experience that sample tracking records are one solution toward a rough estimate of the quality of samples. Although this 'sample tracking records' system does not really provide any detailed information about which samples are of high quality, a record of exposed temperature and elapsed time per each sample lets us to estimate the rough quality of that particular sample. In other words, we can avoid similarly analyzing samples with a 1-month 2808C storage history and one with a 2-year 2208C history. We have no control to assess quality over time right now beside this 'sample tracking records'. A basic study concerning the sample degradation process under various storage conditions (11) is needed.
